<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJPathology</journal-id><journal-title-group><journal-title>Open Journal of Pathology</journal-title></journal-title-group><issn pub-type="epub">2164-6775</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojpathology.2016.61005</article-id><article-id pub-id-type="publisher-id">OJPathology-62940</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Cancers in the Elderly Seen in Anatomical Pathology Laboratory in Lom&#233;, Togo
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>chin</surname><given-names>Darré</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Atchi</surname><given-names>Walla</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tchilabalo</surname><given-names>Matchonna Kpatcha</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdoul-Samadou</surname><given-names>Aboubakari</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nidain</surname><given-names>Maneh</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mikotakatola</surname><given-names>Koulinga</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Koffi</surname><given-names>Amégbor</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gado</surname><given-names>Napo Koura</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff5"><addr-line>Department of Ophthalmology, The University Teaching Hospital of Lomé, Lomé, Togo</addr-line></aff><aff id="aff1"><addr-line>Department of Pathology, The University Teaching Hospital of Lomé, Lomé, Togo</addr-line></aff><aff id="aff4"><addr-line>Department Obstetrics and Gynecology, The University Teaching Hospital of Kara, Kara, Togo</addr-line></aff><aff id="aff3"><addr-line>Department of Urology, The University Teaching Hospital of Lomé, Lomé, Togo</addr-line></aff><aff id="aff2"><addr-line>Department of Trauma and Orthopedic, The University Teaching Hospital of Lomé, Lomé, Togo</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>paolodarre@yahoo.fr(CD)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>01</month><year>2016</year></pub-date><volume>06</volume><issue>01</issue><fpage>26</fpage><lpage>31</lpage><history><date date-type="received"><day>10</day>	<month>December</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>18</month>	<year>January</year>	</date><date date-type="accepted"><day>22</day>	<month>January</month>	<year>2016</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background: The elderly cancers are worldwide a major public health issue. Their exact incidence is unknown in Togo. The purpose of this study was to describe epidemiological and histological data of cancers in the elderly in Togo. Materials and Methods: This was a cross-sectional and descriptive study of cases of elderly cancers diagnosed at the laboratory of pathology of the university teaching hospital of Lom&#233; from 1995 to 2014 (20 years). Cases of examination on samples of the elderly (biopsy, excision, surgical specimens) were collected from the data records of that laboratory. Results: Overall, 792/5200 cases of elderly cancer were collected representing 15.2% of all cancers diagnosed in the laboratory. The annual incidence was 39.6 cases. Patient age ranged from 65 to 103 years old, with a mean of 68.5 &#177; 4 years old. The sex ratio (M/F) was 1.3. At pathological level, the study material included pieces (n=290 cases; 36.6%) and biopsies (n=502 cases; 63.4%). Cancers located preferably in prostate in men (38%), and in women the most frequent locations were cervix (16.2%) and breast (15.8%). We noticed four histological groups: carcinomas (n = 706 cases; 89.1%), sarcomas (n = 43 cases; 5.5%), lymphoma (n = 34 cases; 4.3%) and melanoma (n = 9 cases; 1.1%). Carcinomas were dominated by adenocarcinomas (50.1%) and squamous cell carcinomas (33.8%); Kaposi’s sarcoma (32.6%) was the most common histological type in sarcomas. Conclusion: Our results showed that the elderly cancers were frequent in Togo, locating mostly in uterus cervix and breast in female, and prostate in men. This study could help to advocate the establishment of a cancer registry in Togo.
 
</p></abstract><kwd-group><kwd>Cancer</kwd><kwd> Elderly</kwd><kwd> Togo</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Cancers are a real public health issue. They affect individuals of all ages, but the risk of occurrence and related deaths to cancer rise sharply with age [<xref ref-type="bibr" rid="scirp.62940-ref1">1</xref>] . In Western countries, the significant increase in the population of elderly leads to a raise of the incidence of cancer [<xref ref-type="bibr" rid="scirp.62940-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.62940-ref2">2</xref>] . The duration of carcinogenesis, greater tissue sensitivity to carcinogens and the effects of aging contribute to the development of cancers in older adults [<xref ref-type="bibr" rid="scirp.62940-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.62940-ref4">4</xref>] . In Africa, where emerging non-communicable diseases, chronic diseases such as hypertension and diabetes, studies addressing cancer in the elderly seem few mainly because of the non availability of effective tools for data collection including cancer registries [<xref ref-type="bibr" rid="scirp.62940-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.62940-ref6">6</xref>] .</p><p>The purpose of this study was to describe the epidemiological and histological aspects of cancer among subjects aged 65 and over in Togo. These data could help to strengthen advocacy for the establishment of a registry of cancer.</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>We conducted a retrospective and descriptive study of all cases of cancer among subjects aged 65years and older diagnosed between January 1995 and December 2014 (20 years) in the laboratory of pathology of the university teaching hospital of Lom&#233;. These cases were collected from the records of that laboratory. The samples examination techniques consisted primarily of paraffin embedded (56˚C - 60˚C) and then stained with hematoxylin eosin. The variables studied were epidemiological (gender, age, origin) and histological data (seat, histological type).</p></sec><sec id="s3"><title>3. Statistical Analysis</title><p>Categorical variables are expressed as counts and percentages and continuous variables are expressed as means and standard deviations (SDs). The processing and data analysis were performed using Epi Info version 3.5.1.</p></sec><sec id="s4"><title>4. Ethical Considerations</title><p>The confidentiality of data banks has been respected according to the ethical rules in force in Togo. This studyreceived approval from theHead of the laboratory department tobe conducted. Since it was counting records, patient consent was not required. However during the countingand data collection patient names were notcollectedin order to preserveconfidentiality.</p></sec><sec id="s5"><title>5. Results</title><sec id="s5_1"><title>5.1. Epidemiology</title><p>We collected during our study period 792 cases of elderly cancer representing 15.2% (5200 cases) of all cancers diagnosed in the Laboratory. The annual incidence was 39.6 cases. We observed 454 cases (57.3%) of males and 338 cases (42.7%) of male subject about a sex ratio (M/F) of 1.3. Patient age ranged from 65 to 103 years old, with a mean of 68.5 &#177; 4 years old. Among males, the mean age was 66.4 &#177; 9 years old and mean age was 71.2 &#177; 3 years old among females. The topographic distribution showed that these cancers preferentially sit in humans to the prostate (n = 171 cases; 38%) and stomach (n = 55 cases; 12.1%); in women the cervix (n = 55 cases; 16.2%) and breast (n = 54 cases; 15.8%) were the most represented sits (<xref ref-type="table" rid="table1">Table 1</xref>).</p></sec><sec id="s5_2"><title>5.2. Histology</title><p>The studied samples were 502 cases (63.4%) of biopsies and 290 cases (36.6%) of surgical specimens. The overall distribution of elderly cancer noted four histological groups: carcinomas (n = 706 cases; 89.1%), sarcomas (n = 43 cases; 5.5%), lymphoma (n = 34 cases; 4.3%) and melanoma (n = 9 cases; 1.1%). Cancers were at a localized stage in 11 cases, all of which 7 carcinoma in situ localized in the breast and 4 in the cervix. Carcinomas were observed at a mean age of 67.4 years, distributed in 397 cases (56.2%) of males and 309 cases (43.8%) of female. The histological types are shown in <xref ref-type="table" rid="table2">Table 2</xref>. We noticed a predominance of adenocarcinoma (n = 354 cases; 44.6%) followed by squamous cell carcinoma (n = 239 cases; 30.2%).</p><p>Sarcomas in the elderly were observed at a mean age of 73.6 years old, distributed in 24 cases (55.8%) in men and 19 cases in women (44.2%). These sarcomas sat in the skin (n = 35cases; 81.4%), digestive tract (n = 5 cases;</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of elderly cancer by site and sex</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >Male</th><th align="center" valign="middle"  colspan="2"  >Female</th><th align="center" valign="middle"  colspan="2"  >Male + Female</th></tr></thead><tr><td align="center" valign="middle" >Seats</td><td align="center" valign="middle" >Number</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >Number</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >Number</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle" >Lips</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.44</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.30</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.38</td></tr><tr><td align="center" valign="middle" >Language</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >1.55</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.59</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >1.14</td></tr><tr><td align="center" valign="middle" >Mouth</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0.88</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.59</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >0.76</td></tr><tr><td align="center" valign="middle" >Salivary Gland</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.66</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.30</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0.51</td></tr><tr><td align="center" valign="middle" >Pharynx</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >1.55</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.89</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >1.26</td></tr><tr><td align="center" valign="middle" >Esophagus</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >6.61</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >1.78</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >4.55</td></tr><tr><td align="center" valign="middle" >Stomach</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >12.11</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >9.17</td><td align="center" valign="middle" >86</td><td align="center" valign="middle" >10.86</td></tr><tr><td align="center" valign="middle" >Small intestine and colon</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >2.20</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >2.66</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >2.40</td></tr><tr><td align="center" valign="middle" >Rectum and anal canal</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >4.40</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >4.14</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >4.29</td></tr><tr><td align="center" valign="middle" >Liver and biliary</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.22</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1.48</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >0.76</td></tr><tr><td align="center" valign="middle" >Pancr&#233;as</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.66</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.30</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0.51</td></tr><tr><td align="center" valign="middle" >Nasal et sinus Fosse</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0.88</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >1.78</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >1.26</td></tr><tr><td align="center" valign="middle" >Larynx</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >1.98</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >2.07</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >1.89</td></tr><tr><td align="center" valign="middle" >Trachea, bronche, lungs</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >2.20</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >2.37</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >2.27</td></tr><tr><td align="center" valign="middle" >Bone and cartilage</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >3.08</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >3.25</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >3.16</td></tr><tr><td align="center" valign="middle" >Skin</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >4.41</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >5.62</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >4.93</td></tr><tr><td align="center" valign="middle" >Soft tissue</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >5.51</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >7.40</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >6.31</td></tr><tr><td align="center" valign="middle" >Breast</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >1.32</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >15.98</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >7.58</td></tr><tr><td align="center" valign="middle" >Vulva</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.89</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.38</td></tr><tr><td align="center" valign="middle" >Vagina</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.59</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.22</td></tr><tr><td align="center" valign="middle" >Cervix</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >16.27</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >6.94</td></tr><tr><td align="center" valign="middle" >Ut&#233;rine body</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >9.47</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >4.04</td></tr><tr><td align="center" valign="middle" >Ovary</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.59</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.25</td></tr><tr><td align="center" valign="middle" >Prostate</td><td align="center" valign="middle" >171</td><td align="center" valign="middle" >37.67</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >171</td><td align="center" valign="middle" >21.59</td></tr><tr><td align="center" valign="middle" >Kidney</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.22</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.89</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0.51</td></tr><tr><td align="center" valign="middle" >Bladder</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >1.32</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >1.18</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >1.26</td></tr><tr><td align="center" valign="middle" >Eye</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.22</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1.48</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >0.76</td></tr><tr><td align="center" valign="middle" >Thyroid</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.22</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.30</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.25</td></tr><tr><td align="center" valign="middle" >Unclear Seat</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >1.98</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >3.85</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >2.78</td></tr><tr><td align="center" valign="middle" >Lymphoid tissue</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >5.51</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >6.80</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >6.06</td></tr><tr><td align="center" valign="middle" >All seats</td><td align="center" valign="middle" >454</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >338</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >792</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><p>11.6%) and breast (n = 3 cases; 7%). The histological types were dominated by Kaposi’s sarcoma (n = 14 cases; 1.8%) and dermatofibrosarcoma (n = 10 cases; 1.3%) (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>Hodgkin lymphomas (HL) were seen in 4 cases and non-Hodgkin in 30 cases. Non-Hodgkin lymphoma (NHL) was dominated by diffuse large B-cell lymphomas (n = 22 cases; 73.33%). Other lymphomas consisted of Malta lymphoma (n = 6 cases; 20%) and T-cell lymphoma (n = 2 cases; 6.67%). The cases of HL were all classic</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of elderly cancer according to histological types and groups</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Histological types</th><th align="center" valign="middle" >Number of cases (n)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >Carcinomas (n = 706)</td></tr><tr><td align="center" valign="middle" >Ad&#233;nocarcinoma</td><td align="center" valign="middle" >354</td><td align="center" valign="middle" >44.70</td></tr><tr><td align="center" valign="middle" >Squamous cell carcinoma</td><td align="center" valign="middle" >239</td><td align="center" valign="middle" >30.18</td></tr><tr><td align="center" valign="middle" >Infiltrating ductal carcinoma</td><td align="center" valign="middle" >59</td><td align="center" valign="middle" >7.45</td></tr><tr><td align="center" valign="middle" >Adenoid cystic carcinoma</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >1.39</td></tr><tr><td align="center" valign="middle" >Mucinous carcinoma</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >1.14</td></tr><tr><td align="center" valign="middle" >Papillary carcinoma</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >0.88</td></tr><tr><td align="center" valign="middle" >Transitional cell carcinoma</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >0.76</td></tr><tr><td align="center" valign="middle" >Clear cell carcinoma</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.38</td></tr><tr><td align="center" valign="middle" >Undifferentiated carcinoma</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.25</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Sarcomas (n = 43)</td></tr><tr><td align="center" valign="middle" >Kaposi sarcoma</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >1.77</td></tr><tr><td align="center" valign="middle" >Dermatofibrosarcoma</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >1.26</td></tr><tr><td align="center" valign="middle" >Fibrosarcoma</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >1.01</td></tr><tr><td align="center" valign="middle" >Rhabdomyosarcoma</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >0.63</td></tr><tr><td align="center" valign="middle" >Leiomyosarcoma</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.38</td></tr><tr><td align="center" valign="middle" >Liposarcoma</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.38</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Lymphomas (n = 34)</td></tr><tr><td align="center" valign="middle" >LNH</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >3.79</td></tr><tr><td align="center" valign="middle" >LH</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0.51</td></tr><tr><td align="center" valign="middle" >Melanomas</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >1.14</td></tr><tr><td align="center" valign="middle" >All of cases</td><td align="center" valign="middle" >792</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><p>shape (3 nodular sclerosis form and 1 form of lymphocyte depletion).</p><p>Nine cases of melanoma were observed of which 8 were located in the lower limbs and 1 in the upper limbs; these melanoma were all observed in 5 men.</p></sec></sec><sec id="s6"><title>6. Discussion</title><sec id="s6_1"><title>6.1. Epidemiology</title><p>The rates of elderly cancer present significant variations through the world. Indeed, data found in northern countries with high technical platform and cancer registries are hardly comparable to those observed in Southern countries in which cancer registry is not available. The continuous and comprehensive record of all cases of cancer (cancer registry) is a guarantor of the quality of data and allows an approach to estimate the impact and the different epidemiological settings [<xref ref-type="bibr" rid="scirp.62940-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.62940-ref3">3</xref>] .</p><p>Thus, in our study, the elderly cancers represented 15.2% of all cancers, comparable to the rate reported in Congo-Nkoua M’Bon which was 17.4%, but very low compared to rates observed in Europe (60%) and USA (65%) [<xref ref-type="bibr" rid="scirp.62940-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.62940-ref8">8</xref>] . Cancers of the elderly were observed in both sexes with a slight male predominance; Nkoua M’Bon had reported a female predominance (63.1%) [<xref ref-type="bibr" rid="scirp.62940-ref7">7</xref>] . In the United States, cancer of the elderly occurred in the proportions of 54% in men and 46% in women [<xref ref-type="bibr" rid="scirp.62940-ref9">9</xref>] .</p><p>The average age of patients in our study is similar to those of African authors where seniors account for only 5% - 10% of the whole population [<xref ref-type="bibr" rid="scirp.62940-ref7">7</xref>] . In Western countries, the population projections for the next fifty years predict an increase in the number of cancers associated with aging [<xref ref-type="bibr" rid="scirp.62940-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.62940-ref10">10</xref>] . It appears in our study topographical distribution identical to that of Nkoua M’Bon in Congo [<xref ref-type="bibr" rid="scirp.62940-ref7">7</xref>] . Indeed, in older men, prostate cancer is predominant while cervical and breast cancers are prevalent in elderly women. In France and the United States, the four most common cancers in the population aged 65 years and over are prostate cancer in men with an average age of 69 years, cervical and breast cancer in women at an average age of 66 years, and colorectal cancers and broncho- pulmonary in both sexes [<xref ref-type="bibr" rid="scirp.62940-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.62940-ref3">3</xref>] .</p></sec><sec id="s6_2"><title>6.2. Histology</title><p>Carcinomas were the most frequent histological group in our study, dominated by prostatic adenocarcinoma and digestive localizations. The predominant histological type was invasive ductal carcinoma, and in squamous cell carcinoma in the cervix. Indeed, if there is evidence of reduced mortality factors for breast cancer, colorectal cancer and cervical cancer through screening in the population under 65, few studies have included people of 70 and over [<xref ref-type="bibr" rid="scirp.62940-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.62940-ref11">11</xref>] . The main goal of the screening is to reduce mortality by the diagnosis and treatment at an early stage of the disease [<xref ref-type="bibr" rid="scirp.62940-ref11">11</xref>] .</p><p>Sarcomas represented the second histological group of elderly cancer, dominated by Kaposi’s sarcoma. It is endemic in Africa with variable rates between 4 and 38% versus rates below 1% in Asia and Europe [<xref ref-type="bibr" rid="scirp.62940-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.62940-ref13">13</xref>] . In black Africa, with the advent of HIV infection, the incidence of Kaposi’s sarcoma has increased in all countries [<xref ref-type="bibr" rid="scirp.62940-ref12">12</xref>] . The dermatofibrosarcoma are relatively common, with no apparent predisposing cause and are seen in both gender. These cancers have no epidemiological particularity in Africa [<xref ref-type="bibr" rid="scirp.62940-ref12">12</xref>] . Lymphomas occupied the third place among cancers in the elderly. They were mostly non-Hodgkin lymphomas in our study. In France, the increase in life expectancy now estimated at 77 years for men and 84 years for women, foreshadows a steady increase in the coming years in the incidence of NHL in the elderly [<xref ref-type="bibr" rid="scirp.62940-ref14">14</xref>] . It can be estimated that about one third of the new NHL diagnoses are worn today in subjects over 65 years [<xref ref-type="bibr" rid="scirp.62940-ref15">15</xref>] . Lymphomas diffuse large B cells were the most common in our study; they comprise 30% to 40% of the lymphoma in developed countries. [<xref ref-type="bibr" rid="scirp.62940-ref16">16</xref>] The age of the patient has been recognized as a key prognostic factor, being among those of the International Prognostic Index of the most discriminating aggressive lymphomas for the long-term survival (41% survival at 5 years for subjects over 60 years versus 60% for the youngest) [<xref ref-type="bibr" rid="scirp.62940-ref16">16</xref>] .</p><p>Melanomas in the elderly were uncommon in our study (1.14%), confirming the trend that it is a rare disease in the black race. In South Africa, its rates vary between 0.5 and 1.8 cases per year per 100,000 population among black Africans against 4.4 to 6.2 per 100,000 per year in whites people [<xref ref-type="bibr" rid="scirp.62940-ref17">17</xref>] . It has been shown that advancing age is a pejorative factor independent of other prognostic factors for melanoma usually accepted [<xref ref-type="bibr" rid="scirp.62940-ref18">18</xref>] . It is however unclear whether this fact is due to a particular biological behavior of melanoma that develop in the aged individual with reduced immune defenses of the host, or both [<xref ref-type="bibr" rid="scirp.62940-ref17">17</xref>] . Although in some European studies there was a slight female predominance, all recent studies worldwide have shown a tendency to equality of its rate in both genders [<xref ref-type="bibr" rid="scirp.62940-ref19">19</xref>] .</p></sec></sec><sec id="s7"><title>7. Conclusion</title><p>The elderly cancers are frequent in our country, in spite of the quality of data available because of lack of cancer registry. Prostate cancer in men, cervical and breast cancers in women were the most common cancer in the elderly. This study also allowed us to have knowledge on different histological types of elderly cancer dominated by adenocarcinomas. In light of this work, we advocate the installation of a cancer registry and the establishment of a free cancer care in the elderly.</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The authors reported no conflict of interest.</p></sec><sec id="s9"><title>Authors Contributions</title><p>TD: supervised for the design of the study, undertook the field study, performed data collection, analysis and interpretation of the results, and wrote the manuscript. AW, TMK, ASA, NM, and MK participated in the design of the study, supervised the data collection and participated in the data analysis. KA and NG were responsible for the overall scientific management of the study, the analysis and interpretation, and preparation of the final manuscript. All authors have read and approved the final manuscript to be submitted for publication</p></sec><sec id="s10"><title>Cite this paper</title><p>TchinDarr&#233;,AtchiWalla,Tchilabalo MatchonnaKpatcha,Abdoul-SamadouAboubakari,NidainManeh,MikotakatolaKoulinga,KoffiAm&#233;gbor,Gado NapoKoura, (2016) Cancers in the Elderly Seen in Anatomical Pathology Laboratory in Lom&#233;, Togo. Open Journal of Pathology,06,26-31. doi: 10.4236/ojpathology.2016.61005</p></sec><sec id="s11"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.62940-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Gonsalves, W. and Ganti, A.K. (2011) Targeted Anti-Cancer Therapy in the Elderly. Critical Reviews in Oncology/ Hematology, 78, 227-242. http://dx.doi.org/10.1016/j.critrevonc.2010.06.001</mixed-citation></ref><ref id="scirp.62940-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Balducci, L. and Extermann, M. (2001) A Practical Approach to the Older Patients with Cancer. Current Problems in Cancer, 25, 7-76. http://dx.doi.org/10.1053/cn.2001.v25.111579</mixed-citation></ref><ref id="scirp.62940-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Franceschi, S. and La Vecchia, C. (2001) Cancer Epidemiology in the Elderly. Critical Reviews in Oncology/Hematology, 39, 219-226. http://dx.doi.org/10.1016/S1040-8428(01)00102-0</mixed-citation></ref><ref id="scirp.62940-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Micheli, A., Mugno, E., Krogh, V., Quinn, M.J., Coleman, M., Hakulinen, T., et al. (2002) Cancer Prevalence in European Registry Areas. Annals of Oncology, 13, 840-865. http://dx.doi.org/10.1093/annonc/mdf127</mixed-citation></ref><ref id="scirp.62940-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Verdier, F. and Fourcade, L. (2007) Evolution of Cardiovascular Risk Factors in Developing Countries. Trop Med, 67, 552-558.</mixed-citation></ref><ref id="scirp.62940-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Droz, J.P., Dunet Rodde, M.H. and Vitoux, A. (2008) Development of Geriatric Oncology: National and International Policy Aspects. Bulletin du Cancer, 95, 104-107.</mixed-citation></ref><ref id="scirp.62940-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Nkoua M’Bon, J.B., Nsondé Malanda, J. and Moukassa, D. (2011) Cancers in the Elderly in Brazzaville. Carcinol Clin Afrique, 10, 43-46.</mixed-citation></ref><ref id="scirp.62940-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hill, C. and Doyon, F. (2008) The Incidence of Cancer in the Elderly. Bulletin du Cancer, 95, 7-10</mixed-citation></ref><ref id="scirp.62940-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Edwards, B.K., Howe, H.L., Ries, L.A., Thun, M.J., Rosenberg, H.M., Yancik, R., et al. (2002) Annual Report to the Nation on the Status of Cancer, 1973-1999, Featuring Implications of Age and Aging on U.S. Cancer Burden. Cancer, 94, 2766-2792. http://dx.doi.org/10.1002/cncr.10593</mixed-citation></ref><ref id="scirp.62940-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Repetto, L. and Balducci, L. (2002) A Case for Geriatric Oncology. The Lancet Oncology, 3, 289-297. http://dx.doi.org/10.1016/S1470-2045(02)00730-1</mixed-citation></ref><ref id="scirp.62940-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Walter, L.C., Lewis, C.L. and Barton, M.B. (2005) Screening for Colorectal, Breast, and Cervical Cancer in the Elderly: A Review of the Evidence. American Journal of Medicine, 118, 1078-1086. http://dx.doi.org/10.1016/j.amjmed.2005.01.063</mixed-citation></ref><ref id="scirp.62940-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Friedman-Kein, A.E. and Salteman, B. (1990) Clinical Manifestations of Classical, Endemic African, and Epidemic AIDS-Associated Kaposi’s Sarcoma. Journal of the American Academy of Dermatology, 22, 1237-1250. http://dx.doi.org/10.1016/0190-9622(90)70169-I</mixed-citation></ref><ref id="scirp.62940-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Terret, C. (2008) Geriatric Oncology: Patient Assessment-Old with Cancer. Bulletin du Cancer, 95, 16-20</mixed-citation></ref><ref id="scirp.62940-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Thieblemont, C. and Coiffier, B. (2007) Lymphoma in Older Patients. Journal of Clinical Oncology, 25, 1916-1923. http://dx.doi.org/10.1200/JCO.2006.10.5957</mixed-citation></ref><ref id="scirp.62940-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Swenson, W.T., Wooldridge, J.E., Lynch, C.F., Forman-Hoffman, V.L., Chrischilles, E. and Link, B.K. (2005) Improved Survival of Follicular Lymphoma Patients in the United States. Journal of Clinical Oncology, 23, 5019-5026. http://dx.doi.org/10.1200/JCO.2005.04.503</mixed-citation></ref><ref id="scirp.62940-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Engert, A., Ballova, V., Haverkamp, H., Pfistner, B., Josting, A., Dühmke, E., et al. (2005) Hodgkin’s Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis from the German Hodgkin’s Study Group. Journal of Clinical Oncology, 23, 5052-5060. http://dx.doi.org/10.1200/JCO.2005.11.080</mixed-citation></ref><ref id="scirp.62940-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Seidler, A.M., Pennie, M.L., Veledar, E., Culler, S.D. and Chen, S.C. (2010) Economic Burden of Melanoma in the Elderly Population. JAMA Dermatology, 146, 249-256. http://dx.doi.org/10.1001/archdermatol.2009.389</mixed-citation></ref><ref id="scirp.62940-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Swetter, S.M., Boldrick, J.C., Jung, S.Y., Egbert, B.M. and Harvell, J.D. (2005) Increasing Incidence of Lentigo Maligna Melanoma Subtypes: Northern California and National Trends from 1990 to 2000. Journal of Investigative Dermatology, 125, 685-691. http://dx.doi.org/10.1111/j.0022-202X.2005.23852.x</mixed-citation></ref><ref id="scirp.62940-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Nagore, E., Hueso, L., Botella-Estrada, R., Alfaro-Rubio, A., Serna, I., Guallar, J., et al. (2010) Smoking, Sun Exposure, Number of Nevi and Previous Neoplasias Are Factoring Risk for Melanoma in Older Patients (60 Years and over). Journal of the European Academy of Dermatology and Venereology, 24, 50-57. http://dx.doi.org/10.1111/j.1468-3083.2009.03353.x</mixed-citation></ref></ref-list></back></article>